Faricimab for treating wet age-related macular degeneration

2.1 Faricimab (Vabysmo, Roche) is indicated for 'the treatment of adults with neovascular (wet) age-related macular degeneration'.

2.2 The dosage schedule is available in the summary of product characteristics for faricimab.

2.3 Faricimab costs £857 for 1 vial of 120 mg per 1 ml solution for injection (excluding VAT; company submission, accessed April 2022).

2.4 The company has a commercial arrangement. This makes faricimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.